

640-1815 #
1-13

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.

WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE (202) 371-2540, (202) 371-6566

MAR 6 1998

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL O. LEE
G. KEVIN TOWNSEND*
JOHN M. COVERT*

LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
STEVEN R. LUDWIG
MICHAEL V. MESSINGER
JUDITH U. KIM*
KEITH KIND*
TIMOTHY J. SHEA, JR.*
DONALD R. MCPHAIL
PATRICK E. GARRETT
BARBARA A. PARVIS
MICHAEL A. RAHMAN*
STEPHEN G. WHITESIDE*
NOEL B. WHITLEY*

RICK A. TOERING*
JEFFREY T. HELVEY*
DUANE S. KOBAYASHI
RICHARD A. DUNNING, JR.
KIMBERLIN M. TOOHEY
RALPH P. ALBRECHT
HEIDI L. KRAUS*
JEFFREY R. KURIN*
CARL B. MASSEY, JR.*
RAYMOND MILLIEN*
PATRICK D. O'BRIEN*
BRIAN S. ROSENBLUM*

DONALD J. FEATHERSTONE**
LAWRENCE B. BUGAISKY**
KAREN R. MARKOWICZ**
GRANT E. REED**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

WRITER'S DIRECT NUMBER:

INTERNET ADDRESS:

March 4, 1998

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Continuation Patent Application
Appl. No. 08/836,576; Filed: September 9, 1997
For: **Adjuvant for Vaccine Composition**
Inventors: HAENSLER *et al.*
Our Ref: 0725.0100001/SLF/GER

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement and Fee Under 37 C.F.R. § 1.97(c);
2. Form PTO-1449 two (2) pages, citing four (4) documents;
3. A copy of each of the four (4) cited documents;

Assistant Commissioner for Patents

March 4, 1998

Page 2

4. Our Check No. 21223 in the amount of \$240.00 to cover:


\$240.00 Submission of an IDS (37 C.F.R. § 1.97(c)); and
5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Grant E. Reed
Agent for Applicants
Registration No. 41,264

7 3/22/98
16ray

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

HAENSLER *et al.*

Appl. No. 08/836,576

Filed: September 9, 1997

For: **Adjuvant For a Vaccine
Composition**

Art Unit: 1815

Examiner: Brumback, D.

Atty. Docket: 0725.0100001/SLF/GER

**First Supplemental Information Disclosure Statement
and Fee Under 37 C.F.R. § 1.97(c)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in the Applicants' Information Disclosure Statement filed on October 17, 1997 in connection with the above-captioned application.

The Examiner is also referred to the following co-pending U.S. patent applications, which are directed to related technical subject matter: Appl. No. 08/903,978, filed July 31, 1997, which

is a continuation application of Appl. No. 08/466,244, filed June 6, 1995. The identification of these U.S. patent applications is not to be construed as a waiver of secrecy as to these applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

1/1998 DALEXAND 00000012 08836576
C:126 240.00 (p)

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).


It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

In accordance with 37 C.F.R. § 1.97(c), fee payment under 37 C.F.R. § 1.17(p) is provided in our accompanying Check No. 21223. The U.S. Patent and Trademark Office is

hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Grant E. Reed
Agent for Applicants
Registration No. 41,264

Date: March 4, 1998

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600